News & Updates
Filter by Specialty:
Novel genetic element ties valine metabolism to heart failure in T2D
A new study presented at the recent 2022 Scientific Sessions of the American Diabetes Association (ADA 2022) has identified a novel genetic locus associated with heart failure (HF) risk among patients with type 2 diabetes (T2D). This locus appears to play a role in the metabolism of valine, a branched chain amino acid.
Novel genetic element ties valine metabolism to heart failure in T2D
09 Jun 2022Weight loss intervention may improve COPD symptoms
In addition to cardiometabolic benefits, a lifestyle intervention aimed at weight loss in patients with chronic obstructive pulmonary disease (COPD) who are overweight or obese may reduce COPD symptoms, according to results of the INSIGHT COPD trial presented at ATS 2022.
Weight loss intervention may improve COPD symptoms
07 Jun 2022Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022NAFLD tied to CVD risk even in lean patients
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.